Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cuprina Holdings (Cayman) Limited Class A ( (CUPR) ) has provided an announcement.
On July 21, 2025, Cuprina Holdings announced the appointment of Dr. Ronald A. Sherman as Medical and Scientific Director, effective September 15, 2025. The company also signed a licensing agreement with Dr. Sherman for the FDA-approved Lucilia sericata Medical Maggots, marking a significant step in expanding their maggot debridement therapy offerings in the U.S. market. This strategic move is expected to enhance Cuprina’s clinical expertise and regulatory capabilities, potentially increasing the adoption of minimally invasive wound care techniques globally.
More about Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company focused on developing and commercializing products for chronic wound management and the health and beauty sectors. The company specializes in utilizing natural materials to create wound care products that meet international standards.
Average Trading Volume: 209,641
Learn more about CUPR stock on TipRanks’ Stock Analysis page.